Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 345

1.

Comorbid anxiety, depression, and cognition in MS and other immune-mediated disorders.

Whitehouse CE, Fisk JD, Bernstein CN, Berrigan LI, Bolton JM, Graff LA, Hitchon CA, Marriott JJ, Peschken CA, Sareen J, Walker JR, Stewart SH, Marrie RA; CIHR Team in Defining the Burden and Managing the Effects of Psychiatric Comorbidity in Chronic Immunoinflammatory Disease.

Neurology. 2019 Jan 11. pii: 10.1212/WNL.0000000000006854. doi: 10.1212/WNL.0000000000006854. [Epub ahead of print]

PMID:
30635487
2.

MRI utilization during the diagnostic and post-diagnostic phases in multiple sclerosis.

Wijnands JMA, Ekuma O, Kingwell E, Zhu F, Zhao Y, Fisk JD, Evans C, Tremlett H, Marrie RA.

Mult Scler Relat Disord. 2018 Dec 23;28:138-144. doi: 10.1016/j.msard.2018.12.030. [Epub ahead of print]

PMID:
30594814
3.
4.

Diabetes and anxiety adversely affect cognition in multiple sclerosis.

Marrie RA, Patel R, Figley CR, Kornelsen J, Bolton JM, Graff L, Mazerolle EL, Marriott JJ, Bernstein CN, Fisk JD; Comorbidity and Cognition in Multiple Sclerosis (CCOMS) Study Group.

Mult Scler Relat Disord. 2019 Jan;27:164-170. doi: 10.1016/j.msard.2018.10.018. Epub 2018 Oct 23.

5.

Adverse psychiatric effects of disease-modifying therapies in multiple Sclerosis: A systematic review.

Gasim M, Bernstein CN, Graff LA, Patten SB, El-Gabalawy R, Sareen J, Bolton JM, Marriott JJ, Fisk JD, Marrie RA; CIHR team “Defining the burden and managing the effects of psychiatric comorbidity in chronic inflammatory disease”.

Mult Scler Relat Disord. 2018 Nov;26:124-156. doi: 10.1016/j.msard.2018.09.008. Epub 2018 Sep 12. Review.

6.

Paranormal belief, thinking style preference and susceptibility to confirmatory conjunction errors.

Rogers P, Fisk JE, Lowrie E.

Conscious Cogn. 2018 Oct;65:182-196. doi: 10.1016/j.concog.2018.07.013. Epub 2018 Sep 8.

PMID:
30199770
7.

A test of the CaR-FA-X mechanisms and depression in adolescents.

Fisk J, Ellis JA, Reynolds SA.

Memory. 2018 Sep 5:1-10. doi: 10.1080/09658211.2018.1518457. [Epub ahead of print]

PMID:
30182812
8.

Identifying optic neuritis and transverse myelitis using administrative data.

Marrie RA, Ekuma O, Wijnands JMA, Kingwell E, Zhu F, Zhao Y, Fisk JD, Evans C, Tremlett H.

Mult Scler Relat Disord. 2018 Oct;25:258-264. doi: 10.1016/j.msard.2018.08.013. Epub 2018 Aug 13.

PMID:
30144696
9.

Mining healthcare data for markers of the multiple sclerosis prodrome.

Högg T, Wijnands JMA, Kingwell E, Zhu F, Lu X, Evans C, Fisk JD, Marrie RA, Zhao Y, Tremlett H.

Mult Scler Relat Disord. 2018 Oct;25:232-240. doi: 10.1016/j.msard.2018.08.007. Epub 2018 Aug 8.

PMID:
30121490
10.

Factors associated with perceived need for mental health care in multiple sclerosis.

Orr J, Bernstein CN, Graff LA, Patten SB, Bolton JM, Sareen J, Marriott JJ, Fisk JD, Marrie RA; CIHR Team in Defining the Burden and Managing the Effects of Immune-mediated Inflammatory Disease.

Mult Scler Relat Disord. 2018 Oct;25:179-185. doi: 10.1016/j.msard.2018.07.043. Epub 2018 Jul 29.

11.

Increased Burden of Psychiatric Disorders in Inflammatory Bowel Disease.

Bernstein CN, Hitchon CA, Walld R, Bolton JM, Sareen J, Walker JR, Graff LA, Patten SB, Singer A, Lix LM, El-Gabalawy R, Katz A, Fisk JD, Marrie RA; CIHR Team in Defining the Burden and Managing the Effects of Psychiatric Comorbidity in Chronic Immunoinflammatory Disease.

Inflamm Bowel Dis. 2019 Jan 10;25(2):360-368. doi: 10.1093/ibd/izy235.

PMID:
29986021
12.

Five years before multiple sclerosis onset: Phenotyping the prodrome.

Wijnands JM, Zhu F, Kingwell E, Zhao Y, Ekuma O, Lu X, Evans C, Fisk JD, Marrie RA, Tremlett H.

Mult Scler. 2018 Jul 1:1352458518783662. doi: 10.1177/1352458518783662. [Epub ahead of print]

PMID:
29979093
13.

Psychiatric comorbidity increases mortality in immune-mediated inflammatory diseases.

Marrie RA, Walld R, Bolton JM, Sareen J, Patten SB, Singer A, Lix LM, Hitchon CA, El-Gabalawy R, Katz A, Fisk JD, Bernstein CN; CIHR Team in Defining the Burden and Managing the Effects of Psychiatric Comorbidity in Chronic Immunoinflammatory Disease.

Gen Hosp Psychiatry. 2018 Jul - Aug;53:65-72. doi: 10.1016/j.genhosppsych.2018.06.001. Epub 2018 Jun 7.

14.

The association of fatigue, pain, depression and anxiety with work and activity impairment in immune mediated inflammatory diseases.

Enns MW, Bernstein CN, Kroeker K, Graff L, Walker JR, Lix LM, Hitchon CA, El-Gabalawy R, Fisk JD, Marrie RA; CIHR Team in Defining the Burden and Managing the Effects of Psychiatric Comorbidity in Chronic Immunoinflammatory Disease.

PLoS One. 2018 Jun 7;13(6):e0198975. doi: 10.1371/journal.pone.0198975. eCollection 2018.

15.

Comorbidities Are Associated with Altered Health Services Use in Multiple Sclerosis: A Prospective Cohort Study.

McKay KA, Marrie RA, Fisk JD, Patten SB, Tremlett H.

Neuroepidemiology. 2018;51(1-2):1-10. doi: 10.1159/000488799. Epub 2018 May 15.

PMID:
29763935
16.

Diagnoses of Depression and Anxiety Versus Current Symptoms and Quality of Life in Multiple Sclerosis.

Marrie RA, Patten SB, Berrigan LI, Tremlett H, Wolfson C, Warren S, Leung S, Fiest KM, McKay KA, Fisk JD; CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis (ECoMS).

Int J MS Care. 2018 Mar-Apr;20(2):76-84. doi: 10.7224/1537-2073.2016-110.

17.

The Validity and Reliability of Screening Measures for Depression and Anxiety Disorders in Inflammatory Bowel Disease.

Bernstein CN, Zhang L, Lix LM, Graff LA, Walker JR, Fisk JD, Patten SB, Hitchon CA, Bolton JM, Sareen J, El-Gabalawy R, Marriott J, Marrie RA; CIHR Team in Defining the Burden and Managing the Effects of Immune-mediated Inflammatory Disease.

Inflamm Bowel Dis. 2018 Apr 13. doi: 10.1093/ibd/izy068. [Epub ahead of print]

PMID:
29668911
18.

Mapping the Plasticity of the Escherichia coli Genetic Code with Orthogonal Pair-Directed Sense Codon Reassignment.

Schmitt MA, Biddle W, Fisk JD.

Biochemistry. 2018 May 15;57(19):2762-2774. doi: 10.1021/acs.biochem.8b00177. Epub 2018 Apr 27.

PMID:
29668270
19.

Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study.

Wijnands JMA, Zhu F, Kingwell E, Fisk JD, Evans C, Marrie RA, Zhao Y, Tremlett H.

J Neurol Neurosurg Psychiatry. 2018 Oct;89(10):1050-1056. doi: 10.1136/jnnp-2017-317493. Epub 2018 Mar 30.

PMID:
29602795
20.

Psychiatric comorbidity is associated with disability progression in multiple sclerosis.

McKay KA, Tremlett H, Fisk JD, Zhang T, Patten SB, Kastrukoff L, Campbell T, Marrie RA; CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis.

Neurology. 2018 Apr 10;90(15):e1316-e1323. doi: 10.1212/WNL.0000000000005302. Epub 2018 Mar 9.

PMID:
29523642
21.

Validation of the PHQ-9 for Suicidal Ideation in Persons with Inflammatory Bowel Disease.

Litster B, Bernstein CN, Graff LA, Walker JR, Fisk JD, Patten SB, Bolton JM, Sareen J, El-Gabalawy R, Marrie RA.

Inflamm Bowel Dis. 2018 Jul 12;24(8):1641-1648. doi: 10.1093/ibd/izy032.

PMID:
29522100
22.

Resting State BOLD Variability in Alzheimer's Disease: A Marker of Cognitive Decline or Cerebrovascular Status?

Scarapicchia V, Mazerolle EL, Fisk JD, Ritchie LJ, Gawryluk JR.

Front Aging Neurosci. 2018 Feb 21;10:39. doi: 10.3389/fnagi.2018.00039. eCollection 2018.

23.

Preclinical Analysis of JAA-F11, a Specific Anti-Thomsen-Friedenreich Antibody via Immunohistochemistry and In Vivo Imaging.

Karacosta LG, Fisk JC, Jessee J, Tati S, Turner B, Ghazal D, Ludwig R, Johnson H, Adams J, Sajjad M, Koury S, Roy R, Olson JR, Rittenhouse-Olson K.

Transl Oncol. 2018 Apr;11(2):450-466. doi: 10.1016/j.tranon.2018.01.008. Epub 2018 Feb 22.

24.

Increased Burden of Psychiatric Disorders in Rheumatoid Arthritis.

Marrie RA, Hitchon CA, Walld R, Patten SB, Bolton JM, Sareen J, Walker JR, Singer A, Lix LM, El-Gabalawy R, Katz A, Fisk JD, Bernstein CN; Canadian Institutes of Health Research Team in Defining the Burden and Managing the Effects of Psychiatric Comorbidity in Chronic Immunoinflammatory Disease.

Arthritis Care Res (Hoboken). 2018 Jul;70(7):970-978. doi: 10.1002/acr.23539. Epub 2018 May 21.

25.

Executive processes and timing: Comparing timing with and without reference memory.

Ogden RS, MacKenzie-Phelan R, Mongtomery C, Fisk JE, Wearden JH.

Q J Exp Psychol (Hove). 2018 Jan 1:1747021817751869. doi: 10.1177/1747021817751869. [Epub ahead of print]

PMID:
29355468
26.

Physical comorbidities increase the risk of psychiatric comorbidity in immune-mediated inflammatory disease.

Marrie RA, Walld R, Bolton JM, Sareen J, Walker JR, Patten SB, Singer A, Lix LM, Hitchon CA, El-Gabalawy R, Katz A, Fisk JD, Bernstein CN; CIHR Team in Defining the Burden and Managing the Effects of Psychiatric Comorbidity in Chronic Immunoinflammatory Disease.

Gen Hosp Psychiatry. 2018 Mar - Apr;51:71-78. doi: 10.1016/j.genhosppsych.2018.01.003. Epub 2018 Jan 11.

PMID:
29353127
27.

Effects of Psychiatric Comorbidity in Immune-Mediated Inflammatory Disease: Protocol for a Prospective Study.

Marrie RA, Graff L, Walker JR, Fisk JD, Patten SB, Hitchon CA, Lix LM, Bolton J, Sareen J, Katz A, Berrigan LI, Marriott JJ, Singer A, El-Gabalawy R, Peschken CA, Zarychanski R, Bernstein CN.

JMIR Res Protoc. 2018 Jan 17;7(1):e15. doi: 10.2196/resprot.8794.

28.

Effects of physical comorbidities on disability progression in multiple sclerosis.

Zhang T, Tremlett H, Zhu F, Kingwell E, Fisk JD, Bhan V, Campbell T, Stadnyk K, Carruthers R, Wolfson C, Warren S, Marrie RA; CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis.

Neurology. 2018 Jan 30;90(5):e419-e427. doi: 10.1212/WNL.0000000000004885. Epub 2018 Jan 3.

PMID:
29298855
29.

Corrigendum to "Humanization of JAA-F11, a Highly Specific Anti-Thomsen-Friedenreich Pancarcinoma Antibody and In Vitro Efficacy Analysis" [Neoplasia 19.9 (2017) 716-733].

Tati S, Fisk JC, Abdullah J, Karacosta L, Chrisikos T, Philbin P, Morey S, Ghazal D, Zalzala F, Jessee J, Quataert S, Koury S, Moreno D, Eng JY, Glinsky VV, Glinskii OV, Sesay M, Gebhard AW, Birthare K, Olson JR, Rittenhouse-Olson K.

Neoplasia. 2018 Jan;20(1):118. doi: 10.1016/j.neo.2017.10.001. No abstract available.

30.

The validity and reliability of screening measures for depression and anxiety disorders in multiple sclerosis.

Marrie RA, Zhang L, Lix LM, Graff LA, Walker JR, Fisk JD, Patten SB, Hitchon CA, Bolton JM, Sareen J, El-Gabalawy R, Marriott JJ, Bernstein CN.

Mult Scler Relat Disord. 2018 Feb;20:9-15. doi: 10.1016/j.msard.2017.12.007. Epub 2017 Dec 16.

31.

Estimating annual prevalence of depression and anxiety disorder in multiple sclerosis using administrative data.

Marrie RA, Walld R, Bolton JM, Sareen J, Walker JR, Patten SB, Singer A, Lix LM, Hitchon CA, El-Gabalawy R, Katz A, Fisk JD, Bernstein CN; CIHR Team in Defining the Burden and Managing the Effects of Psychiatric Comorbidity in Chronic Immunoinflammatory Disease.

BMC Res Notes. 2017 Nov 25;10(1):619. doi: 10.1186/s13104-017-2958-1.

32.

Comorbidity increases the risk of relapse in multiple sclerosis: A prospective study.

Kowalec K, McKay KA, Patten SB, Fisk JD, Evans C, Tremlett H, Marrie RA; CIHR Team in Epidemiology and Impact of Comorbidity on Multiple Sclerosis (ECoMS).

Neurology. 2017 Dec 12;89(24):2455-2461. doi: 10.1212/WNL.0000000000004716. Epub 2017 Nov 8.

33.

Rising incidence of psychiatric disorders before diagnosis of immune-mediated inflammatory disease.

Marrie RA, Walld R, Bolton JM, Sareen J, Walker JR, Patten SB, Singer A, Lix LM, Hitchon CA, El-Gabalawy R, Katz A, Fisk JD, Bernstein CN; CIHR Team in Defining the Burden and Managing the Effects of Psychiatric Comorbidity in Chronic Immunoinflammatory Disease.

Epidemiol Psychiatr Sci. 2017 Nov 3:1-10. doi: 10.1017/S2045796017000579. [Epub ahead of print]

PMID:
29098977
34.

Paranormal belief and errors of probabilistic reasoning: The role of constituent conditional relatedness in believers' susceptibility to the conjunction fallacy.

Rogers P, Fisk JE, Lowrie E.

Conscious Cogn. 2017 Nov;56:13-29. doi: 10.1016/j.concog.2017.09.010. Epub 2017 Oct 12.

PMID:
29032111
35.

Increased incidence of psychiatric disorders in immune-mediated inflammatory disease.

Marrie RA, Walld R, Bolton JM, Sareen J, Walker JR, Patten SB, Singer A, Lix LM, Hitchon CA, El-Gabalawy R, Katz A, Fisk JD, Bernstein CN; CIHR Team in Defining the Burden and Managing the Effects of Psychiatric Comorbidity in Chronic Immunoinflammatory Disease.

J Psychosom Res. 2017 Oct;101:17-23. doi: 10.1016/j.jpsychores.2017.07.015. Epub 2017 Aug 1.

36.

Humanization of JAA-F11, a Highly Specific Anti-Thomsen-Friedenreich Pancarcinoma Antibody and InVitro Efficacy Analysis.

Tati S, Fisk JC, Abdullah J, Karacosta L, Chrisikos T, Philbin P, Morey S, Ghazal D, Zazala F, Jessee J, Quataert S, Koury S, Moreno D, Eng JY, Glinsky VV, Glinskii OV, Sesay M, Gebhard AW, Birthare K, Olson JR, Rittenhouse-Olson K.

Neoplasia. 2017 Sep;19(9):716-733. doi: 10.1016/j.neo.2017.07.001. Epub 2017 Aug 19. Erratum in: Neoplasia. 2018 Jan;20(1):118.

37.

p53 binding sites in normal and cancer cells are characterized by distinct chromatin context.

Bao F, LoVerso PR, Fisk JN, Zhurkin VB, Cui F.

Cell Cycle. 2017;16(21):2073-2085. doi: 10.1080/15384101.2017.1361064. Epub 2017 Sep 28.

38.

Disease-Modifying Therapies and Adherence in Multiple Sclerosis: Comparing Patient Self-Report with Pharmacy Records.

McKay KA, Evans C, Fisk JD, Patten SB, Fiest K, Marrie RA, Tremlett H.

Neuroepidemiology. 2017;48(3-4):124-130. doi: 10.1159/000477771. Epub 2017 Jul 7.

PMID:
28683461
39.

Lateralized microstructural changes in early-stage Parkinson's disease in anterior olfactory structures, but not in substantia nigra.

Joshi N, Rolheiser TM, Fisk JD, McKelvey JR, Schoffer K, Phillips G, Armstrong M, Khan MN, Leslie RA, Rusak B, Robertson HA, Good KP.

J Neurol. 2017 Jul;264(7):1497-1505. doi: 10.1007/s00415-017-8555-3. Epub 2017 Jun 26.

PMID:
28653210
40.

Cholinesterases in normal and Alzheimer's disease primary olfactory gyrus.

Hamodat H, Cash MK, Fisk JD, Darvesh S.

Neuropathol Appl Neurobiol. 2017 Dec;43(7):571-583. doi: 10.1111/nan.12423. Epub 2017 Jul 21.

PMID:
28644906
41.

Updating of working memory in ecstasy polydrug users: Findings from fNIRS.

Montgomery C, Fisk JE, Roberts CA.

Hum Psychopharmacol. 2017 May;32(3). doi: 10.1002/hup.2609. Epub 2017 Jun 19.

PMID:
28631348
42.

Nearly 400 million people are at higher risk of schistosomiasis because dams block the migration of snail-eating river prawns.

Sokolow SH, Jones IJ, Jocque M, La D, Cords O, Knight A, Lund A, Wood CL, Lafferty KD, Hoover CM, Collender PA, Remais JV, Lopez-Carr D, Fisk J, Kuris AM, De Leo GA.

Philos Trans R Soc Lond B Biol Sci. 2017 Jun 5;372(1722). pii: 20160127. doi: 10.1098/rstb.2016.0127.

43.

Health-care use before a first demyelinating event suggestive of a multiple sclerosis prodrome: a matched cohort study.

Wijnands JMA, Kingwell E, Zhu F, Zhao Y, Högg T, Stadnyk K, Ekuma O, Lu X, Evans C, Fisk JD, Marrie RA, Tremlett H.

Lancet Neurol. 2017 Jun;16(6):445-451. doi: 10.1016/S1474-4422(17)30076-5. Epub 2017 Apr 20.

PMID:
28434855
44.

Increased incidence and prevalence of psoriasis in multiple sclerosis.

Marrie RA, Patten SB, Tremlett H, Wolfson C, Leung S, Fisk JD.

Mult Scler Relat Disord. 2017 Apr;13:81-86. doi: 10.1016/j.msard.2017.02.012. Epub 2017 Feb 20.

45.

Infection-related health care utilization among people with and without multiple sclerosis.

Wijnands JM, Kingwell E, Zhu F, Zhao Y, Fisk JD, Evans C, Marrie RA, Tremlett H.

Mult Scler. 2017 Oct;23(11):1506-1516. doi: 10.1177/1352458516681198. Epub 2016 Dec 21.

PMID:
28273769
46.

Blunted neural response to anticipation, effort and consummation of reward and aversion in adolescents with depression symptomatology.

Rzepa E, Fisk J, McCabe C.

J Psychopharmacol. 2017 Mar;31(3):303-311. doi: 10.1177/0269881116681416. Epub 2017 Jan 16.

PMID:
28093022
47.

Longitudinal changes in microstructural white matter metrics in Alzheimer's disease.

Mayo CD, Mazerolle EL, Ritchie L, Fisk JD, Gawryluk JR; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage Clin. 2016 Dec 16;13:330-338. doi: 10.1016/j.nicl.2016.12.012. eCollection 2017.

48.

Hyperthermostable binding molecules on phage: Assay components for point-of-care diagnostics for active tuberculosis infection.

Zhao N, Spencer J, Schmitt MA, Fisk JD.

Anal Biochem. 2017 Mar 15;521:59-71. doi: 10.1016/j.ab.2016.12.021. Epub 2017 Jan 3.

PMID:
28062210
49.

Screening Tools for Anxiety in People with Multiple Sclerosis: A Systematic Review.

Litster B, Fiest KM, Patten SB, Fisk JD, Walker JR, Graff LA, Bolton JM, Sareen J, Marriott JJ, Berrigan LI, Bernstein CN, Zarychanski R, Singer A, Hitchon CA, Peschken CA, Marrie RA; CIHR Team “Defining the Burden and Managing the Effects of Psychiatric Comorbidity in Chronic Immunoinflammatory Disease”.

Int J MS Care. 2016 Nov-Dec;18(6):273-281. doi: 10.7224/1537-2073.2016-004.

50.

The Major Protein Arginine Methyltransferase in Trypanosoma brucei Functions as an Enzyme-Prozyme Complex.

Kafková L, Debler EW, Fisk JC, Jain K, Clarke SG, Read LK.

J Biol Chem. 2017 Feb 10;292(6):2089-2100. doi: 10.1074/jbc.M116.757112. Epub 2016 Dec 20.

Supplemental Content

Support Center